GUY3, I wasn't ignoring your question in post #80316, in response to my post, but my lengthy response to you got deleted.
A briefer response today, out of courtesy to your question, sure Ocata is a better stock today than it was 10 years ago.
Back then ACTC was working with rats and today they've made it through phase 1, albeit via a horrendous journey for the company and investors and coming perilously close to bankruptcy at one point. That's not necessarily unique to the company, as it's typical of so many start up biotechs.
The question I am focusing on, is Ocata a good investment?
Being at a very critical point now, where their very existence as a stand alone company, let alone ability to meet uplisting requirements or fund continued clinicals and general operating expenses, remains precariously unanswered.
If the company is able to secure necessary operating and uplisting capital, as we hope, the ongoing picture will look much brighter, hopefully than it does right now. I say hopefully, because the question becomes at what price will the company and investors have to pay for financing, whatever form it might take?
Whatever form it takes, it's highly dilutive and the prospect for further dilution, is right around the corner with the 100 mil. shelf and then with more to come for many unknown number of years, assuming the company 'survives' phase 2 clinicals.
Unless you're quite young, are a huge risk taker and truly understands the historically torturous financial and clinical dynamics r and d biotechs go through. imo, it's not a matter of is it a better company than it was 10 years ago, but is it even a good investment?
In my book, NO.
Might there be some trading opps on news, Yes.
The dynamics might well change after phase 2, if Ocata still exists as a stand alone company, which they say is their goal, and phase 2 confirms safety and demonstrates efficacy, but then a brutal phase 3 awaits.
We're already looking a dilution of our dollars invested in the upper 90% range and that's a bad investment.
Why hasn't the investment world exploded with the much anticipated TLD and the Lancet?
I would suggest because of some of the reasons I've noted earlier.
The dynamics of sound investing change if one falls in love with a stock and negates sound investing principals, even for biotechs imo.
